Glück Conviction Score™ ⓘ
ELVN
Enliven Therapeutics, Inc.
Effektiv: Neutral
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
71,5
65 neu, 63 erhöht, 1450,4M $ netto
Aktivist
27,4
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 41.53 | +11.1 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 27.77 | +66.1 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 39.20 | EMA50: 38.88 | |
| MACD-Histogramm | Bullisch | 10 % | 0.570 | Bullisch | |
| RSI(14) | Neutral | 10 % | 65.9 | Neutral (30–70) | |
| Stoch %K(14) | Bärisch | 5 % | 91.2 | Überkauft | |
| ADX(14)+DI | Neutral | 10 % | 20.4 | +DI: 34.7 / −DI: 16.5 | |
| Z-Score(60) | Neutral | 5 % | 1.36 | In Range | |
| 52W-Position | Bullisch | 5 % | 94.0 % | Hoch 48.11 / Tief 15.14 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 104.9 % | Upper 45.51 / Mid 39.17 / Lower 32.83 | |
| LinReg-Slope(60) | Neutral | 10 % | +0.0169 | R²=0.00 / annualisiert +10.5 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | Kunkel Lori Anne | Director | Open Market Sale | -7.779 | 34,28 | -266.659,45 | -129,2% | |
| 2026-06-05 | Kunkel Lori Anne | Director | Open Market Sale | -1.867 | 35,36 | -66.012,08 | -32,0% | |
| 2026-06-05 | Kunkel Lori Anne | Director | Open Market Sale | -354 | 35,82 | -12.679,82 | -6,1% | |
| 2026-05-18 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -223 | 41,21 | -9.188,76 | -4,5% | |
| 2026-05-18 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3.475 | 39,53 | -137.380,65 | -66,6% | |
| 2026-05-18 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.302 | 40,25 | -52.401,98 | -25,4% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -140 | 45,81 | -6.413,50 | -3,1% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.441 | 48,06 | -117.303,48 | -56,9% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.419 | 47,39 | -114.635,44 | -55,6% | |
| 2026-03-25 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -40.000 | 35,10 | -1.404.024,00 | -680,5% | |
| 2026-03-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5.000 | 27,76 | -138.800,00 | -67,3% | |
| 2026-03-10 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -10.129 | 30,19 | -305.826,92 | -148,2% | |
| 2026-03-09 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -29.871 | 30,02 | -896.811,06 | -434,7% | |
| 2026-03-06 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -10.000 | 29,58 | -295.839,00 | -143,4% | |
| 2026-02-17 | Heyman Richard A. | Director | Open Market Sale | -1.230 | 26,18 | -32.196,36 | -15,6% | |
| 2026-02-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -45.000 | 26,17 | -1.177.861,50 | -570,9% | |
| 2026-02-06 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.000 | 29,04 | -145.219,00 | -70,4% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -14.509 | 26,90 | -390.284,85 | -189,2% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.491 | 26,37 | -144.814,14 | -70,2% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -718 | 26,96 | -19.354,41 | -9,4% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -512 | 26,46 | -13.547,11 | -6,6% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -48.057 | 27,98 | -1.344.836,70 | -651,8% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -243 | 28,50 | -6.925,50 | -3,4% | |
| 2026-01-09 | Heyman Richard A. | Director | Open Market Sale | -4.285 | 25,00 | -107.125,43 | -51,9% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -50.000 | 29,13 | -1.456.715,00 | -706,1% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -41.198 | 24,90 | -1.025.863,16 | -497,2% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -1.620 | 25,00 | -40.500,00 | -19,6% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -33.802 | 24,92 | -842.474,29 | -408,3% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -7.500 | 20,13 | -150.961,50 | -73,2% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -8.015 | 25,04 | -200.655,53 | -97,3% | |
| 2025-12-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.000 | 16,84 | -84.206,00 | -40,8% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -4.958 | 20,76 | -102.938,99 | -49,9% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -1.705 | 21,78 | -37.133,88 | -18,0% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12.008 | 22,30 | -267.794,01 | -129,8% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -492 | 23,09 | -11.360,77 | -5,5% | |
| 2025-11-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12.500 | 21,82 | -272.738,75 | -132,2% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.054 | 17,35 | -105.038,72 | -50,9% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -613 | 17,94 | -10.995,44 | -5,3% | |
| 2025-10-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12.500 | 22,08 | -276.025,00 | -133,8% | |
| 2025-10-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12.500 | 21,33 | -266.653,75 | -129,2% | |
| 2025-10-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.667 | 20,10 | -133.992,70 | -64,9% | |
| 2025-09-29 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.250 | 20,40 | -66.291,23 | -32,1% | |
| 2025-09-26 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -3.700 | 20,06 | -74.227,55 | -36,0% | |
| 2025-09-26 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4.000 | 20,25 | -81.005,20 | -39,3% | |
| 2025-09-23 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -2.800 | 20,03 | -56.084,00 | -27,2% | |
| 2025-09-23 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -1.500 | 20,03 | -30.045,00 | -14,6% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4.870 | 19,11 | -93.063,27 | -45,1% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -2.130 | 20,02 | -42.634,08 | -20,7% | |
| 2025-09-19 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -1.000 | 20,25 | -20.250,00 | -9,8% | |
| 2025-09-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -5.000 | 19,09 | -95.473,00 | -46,3% | |
| 2025-09-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.667 | 20,24 | -134.957,41 | -65,4% | |
| 2025-08-27 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.250 | 20,63 | -67.038,73 | -32,5% | |
| 2025-08-21 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -7.500 | 20,01 | -150.099,00 | -72,8% | |
| 2025-08-20 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -1.517 | 20,00 | -30.343,49 | -14,7% | |
| 2025-08-19 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -590 | 20,00 | -11.800,00 | -5,7% | |
| 2025-08-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.000 | 19,62 | -98.117,50 | -47,6% | |
| 2025-08-18 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -10.393 | 20,02 | -208.106,31 | -100,9% | |
| 2025-08-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.262 | 18,20 | -113.948,99 | -55,2% | |
| 2025-08-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -405 | 18,93 | -7.666,53 | -3,7% | |
| 2025-07-28 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.185 | 20,45 | -65.119,24 | -31,6% | |
| 2025-07-28 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -65 | 21,30 | -1.384,52 | -0,7% | |
| 2025-07-21 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -11.924 | 22,26 | -265.458,05 | -128,7% | |
| 2025-07-21 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -576 | 22,90 | -13.187,75 | -6,4% | |
| 2025-07-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -3.663 | 23,37 | -85.606,51 | -41,5% | |
| 2025-07-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -4.687 | 22,69 | -106.359,75 | -51,6% | |
| 2025-07-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -4.150 | 21,58 | -89.551,61 | -43,4% | |
| 2025-07-10 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.000 | 22,66 | -22.655,00 | -11,0% | |
| 2025-07-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.362 | 19,75 | -125.638,68 | -60,9% | |
| 2025-07-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -305 | 20,69 | -6.311,91 | -3,1% | |
| 2025-06-27 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -198 | 21,66 | -4.288,34 | -2,1% | |
| 2025-06-27 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.052 | 20,86 | -63.667,47 | -30,9% | |
| 2025-06-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12.500 | 21,40 | -267.457,50 | -129,6% | |
| 2025-06-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -10.502 | 22,08 | -231.839,00 | -112,4% | |
| 2025-06-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -1.998 | 22,75 | -45.453,30 | -22,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7.959.538 | 7.959.538 | 0 | 312.013.890 | Unverändert | 0,0% | |
| FMR LLC | 6.829.246 | 7.107.635 | -278.389 | 267.706.443 | Reduziert | -3,9% | |
| Polar Capital Holdings Plc | 5.065.933 | 3.513.680 | 1.552.253 | 198.584.574 | Aufgestockt | +44,2% | |
| BlackRock, Inc. | 3.684.707 | 3.613.326 | 71.381 | 144.440.514 | Aufgestockt | +2,0% | |
| Commodore Capital LP | 3.275.000 | 4.692.809 | -1.417.809 | 128.380.000 | Reduziert | -30,2% | |
| Vestal Point Capital, LP | 3.250.000 | 3.830.000 | -580.000 | 127.400.000 | Reduziert | -15,1% | |
| Bellevue Group AG | 2.320.867 | 0 | 2.320.867 | 90.977.986 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.871.515 | 1.442.044 | 429.471 | 73.363.388 | Aufgestockt | +29,8% | |
| Fairmount Funds Management LLC | 1.855.644 | 3.711.444 | -1.855.800 | 72.741.245 | Reduziert | -50,0% | |
| Venrock Adviser, LLC | 1.726.331 | 3.226.331 | -1.500.000 | 67.672.175 | Reduziert | -46,5% | |
| Novo Holdings A/S | 1.280.000 | 1.480.000 | -200.000 | 50.176.000 | Reduziert | -13,5% | |
| VANGUARD GROUP INC | 2.801.665 | 0 | 2.801.665 | 43.145.640 | Neu | +100,0% | |
| STATE STREET CORP | 1.091.106 | 1.052.862 | 38.244 | 42.771.355 | Aufgestockt | +3,6% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.066.420 | 1.048.722 | 17.698 | 41.813.049 | Aufgestockt | +1,7% | |
| Logos Global Management LP | 1.040.000 | 340.000 | 700.000 | 40.768.000 | Aufgestockt | +205,9% | |
| Caption Management, LLC | 956.500 | 0 | 956.500 | 37.494.800 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 929.544 | 1.303.235 | -373.691 | 36.438.125 | Reduziert | -28,7% | |
| BAKER BROS. ADVISORS LP | 905.191 | 271.406 | 633.785 | 35.483.487 | Aufgestockt | +233,5% | |
| Rock Springs Capital Management LP | 826.500 | 798.405 | 28.095 | 32.398.800 | Aufgestockt | +3,5% | |
| Siren, L.L.C. | 746.226 | 0 | 746.226 | 29.252.059 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 681.715 | 398.893 | 282.822 | 26.714.134 | Aufgestockt | +70,9% | |
| First Turn Management, LLC | 623.839 | 0 | 623.839 | 24.454.489 | Neu | +100,0% | |
| Candriam S.C.A. | 594.079 | 453.019 | 141.060 | 23.287.897 | Aufgestockt | +31,1% | |
| Jones Hill Capital LP | 593.040 | 0 | 593.040 | 23.247.168 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 586.904 | 0 | 586.904 | 23.006.637 | Neu | +100,0% | |
| MORGAN STANLEY | 518.572 | 411.823 | 106.749 | 20.328.037 | Aufgestockt | +25,9% | |
| Capital Research Global Investors | 1.304.346 | 0 | 1.304.346 | 20.086.928 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 473.115 | 237.204 | 235.911 | 18.546.108 | Aufgestockt | +99,5% | |
| Avidity Partners Management LP | 400.000 | 140.300 | 259.700 | 15.680.000 | Aufgestockt | +185,1% | |
| NORTHERN TRUST CORP | 372.316 | 352.239 | 20.077 | 14.594.788 | Aufgestockt | +5,7% | |
| Capricorn Fund Managers Ltd | 369.400 | 0 | 369.400 | 14.480.480 | Neu | +100,0% | |
| STEMPOINT CAPITAL LP | 363.438 | 0 | 363.438 | 14.246.770 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 360.577 | 355.192 | 5.385 | 14.134.618 | Aufgestockt | +1,5% | |
| MILLENNIUM MANAGEMENT LLC | 345.318 | 296.947 | 48.371 | 13.536.466 | Aufgestockt | +16,3% | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 330.964 | 0 | 330.964 | 12.973.789 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 329.540 | 30.000 | 299.540 | 12.917.968 | Aufgestockt | +998,5% | |
| Spruce Street Capital LP | 329.006 | 446.084 | -117.078 | 12.897.035 | Reduziert | -26,2% | |
| VANGUARD FIDUCIARY TRUST CO | 312.763 | 0 | 312.763 | 12.260.310 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 310.025 | 0 | 310.025 | 12.152.980 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 309.180 | 0 | 309.180 | 12.119.856 | Neu | +100,0% | |
| 5AM Venture Management, LLC | 772.477 | 0 | 772.477 | 11.896.146 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 771.885 | 36.840 | 735.045 | 11.887.029 | Aufgestockt | +1995,2% | |
| Woodline Partners LP | 301.673 | 301.023 | 650 | 11.825.582 | Aufgestockt | +0,2% | |
| UBS Group AG | 283.544 | 57.868 | 225.676 | 11.114.925 | Aufgestockt | +390,0% | |
| Seven Fleet Capital Management LP | 259.283 | 99.953 | 159.330 | 10.163.894 | Aufgestockt | +159,4% | |
| JANE STREET GROUP, LLC | 246.319 | 116.071 | 130.248 | 9.655.706 | Aufgestockt | +112,2% | |
| Soleus Capital Management, L.P. | 230.869 | 1.025.000 | -794.131 | 9.050.065 | Reduziert | -77,5% | |
| Exome Asset Management LLC | 220.091 | 222.308 | -2.217 | 8.627.567 | Reduziert | -1,0% | |
| Schonfeld Strategic Advisors LLC | 218.867 | 0 | 218.867 | 8.579.586 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 206.572 | 0 | 206.572 | 8.097.622 | Neu | +100,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7.959.538 | 7.959.538 | 0,0% | 312.013.890 | 13,03 |
| FMR LLC | 6.829.246 | 7.107.635 | -3,9% | 267.706.443 | 11,18 |
| Polar Capital Holdings Plc | 5.065.933 | 3.513.680 | +44,2% | 198.584.574 | 8,29 |
| BlackRock, Inc. | 3.684.707 | 3.613.326 | +2,0% | 144.440.514 | 6,03 |
| Commodore Capital LP | 3.275.000 | 4.692.809 | -30,2% | 128.380.000 | 5,36 |
| Vestal Point Capital, LP | 3.250.000 | 3.830.000 | -15,1% | 127.400.000 | 5,32 |
| Bellevue Group AG | 2.320.867 | 0 | +100,0% | 90.977.986 | 3,80 |
| CITADEL ADVISORS LLC | 1.871.515 | 1.442.044 | +29,8% | 73.363.388 | 3,06 |
| Fairmount Funds Management LLC | 1.855.644 | 3.711.444 | -50,0% | 72.741.245 | 3,04 |
| Venrock Adviser, LLC | 1.726.331 | 3.226.331 | -46,5% | 67.672.175 | 2,83 |
| Novo Holdings A/S | 1.280.000 | 1.480.000 | -13,5% | 50.176.000 | 2,09 |
| STATE STREET CORP | 1.091.106 | 1.052.862 | +3,6% | 42.771.355 | 1,79 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.066.420 | 1.048.722 | +1,7% | 41.813.049 | 1,75 |
| Logos Global Management LP | 1.040.000 | 340.000 | +205,9% | 40.768.000 | 1,70 |
| Caption Management, LLC | 956.500 | 0 | +100,0% | 37.494.800 | 1,57 |
| Pictet Asset Management Holding SA | 929.544 | 1.303.235 | -28,7% | 36.438.125 | 1,52 |
| BAKER BROS. ADVISORS LP | 905.191 | 271.406 | +233,5% | 35.483.487 | 1,48 |
| Rock Springs Capital Management LP | 826.500 | 798.405 | +3,5% | 32.398.800 | 1,35 |
| Siren, L.L.C. | 746.226 | 0 | +100,0% | 29.252.059 | 1,22 |
| DIMENSIONAL FUND ADVISORS LP | 681.715 | 398.893 | +70,9% | 26.714.134 | 1,12 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 172 | 65,4 | 2.542 |
| 31.12.2025 | ✓ | 125 | 63,5 | 15.669 |
| 30.09.2025 | ✓ | 133 | 59,8 | 28.205 |
| 30.06.2025 | ✓ | 123 | 59,6 | 27.636 |
| 31.03.2025 | ✓ | 118 | 51,5 | 15.995 |
| 31.12.2024 | ✓ | 111 | 49,8 | 9.501 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Soleus Capital Management, L.P. | 1.025.000 | 15.785.000 |
| Spruce Street Capital LP | 446.084 | 6.869.694 |
| Exome Asset Management LLC | 222.308 | 3.423.543 |
| Trails Edge Capital Partners, LP | 199.306 | 3.069.312 |
| JANE STREET GROUP, LLC | 116.071 | 1.787.493 |
| Seven Fleet Capital Management LP | 99.953 | 1.539.276 |
| Lighthouse Investment Partners, LLC | 65.000 | 1.001.000 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 52.578 | 809.701 |
| Jump Financial, LLC | 45.354 | 698.452 |
| PRUDENTIAL FINANCIAL INC | 35.580 | 547.932 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Vestal Point Capital, LP | 3.830.000 | 2.670.000 | +230.2 % | 58.982.000 |
| Point72 Asset Management, L.P. | 1.504.601 | 464.191 | +44.6 % | 23.170.855 |
| Polar Capital Holdings Plc | 3.513.680 | 418.673 | +13.5 % | 54.110.672 |
| CITADEL ADVISORS LLC | 1.442.044 | 281.541 | +24.3 % | 22.207.477 |
| VANGUARD GROUP INC | 2.801.665 | 248.651 | +9.7 % | 43.145.640 |
| DIMENSIONAL FUND ADVISORS LP | 398.893 | 238.434 | +148.6 % | 6.143.418 |
| Connor, Clark & Lunn Investment Management Ltd. | 194.735 | 159.956 | +459.9 % | 2.998.919 |
| BAKER BROS. ADVISORS LP | 271.406 | 156.573 | +136.3 % | 4.179.652 |
| MORGAN STANLEY | 411.823 | 153.439 | +59.4 % | 6.342.080 |
| Rock Springs Capital Management LP | 798.405 | 112.298 | +16.4 % | 12.295.437 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| FRANKLIN RESOURCES INC | 20.167 | -410.073 | -95.3 % | 310.571 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 23.800 | -207.504 | -89.7 % | 367 |
| HighVista Strategies LLC | 82.536 | -176.599 | -68.1 % | 1.271.055 |
| Candriam S.C.A. | 453.019 | -156.333 | -25.7 % | 6.976.790 |
| JANUS HENDERSON GROUP PLC | 1.671.724 | -121.859 | -6.8 % | 25.744.550 |
| AMERIPRISE FINANCIAL INC | 18.949 | -104.387 | -84.6 % | 291.814 |
| Pictet Asset Management Holding SA | 1.303.235 | -94.852 | -6.8 % | 20.069.819 |
| MILLENNIUM MANAGEMENT LLC | 296.947 | -84.458 | -22.1 % | 4.572.984 |
| NORTHERN TRUST CORP | 352.239 | -42.213 | -10.7 % | 5.424.480 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.048.722 | -36.291 | -3.3 % | 16.153.779 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | Commodore Capital Master LP | Passiv (13G/A) | 7,70 % | 4.800.940 | -2,20 pp | |
| 15.05.2026 | Robert Egen Atkinson | Passiv (13G/A) | 7,70 % | 4.800.940 | -2,20 pp | |
| 15.05.2026 | Michael Kramarz | Passiv (13G/A) | 7,70 % | 4.800.940 | -2,20 pp | |
| 15.05.2026 | Commodore Capital LP | Passiv (13G/A) | 7,70 % | 4.800.940 | -2,20 pp | |
| 15.05.2026 | Venrock Healthcare Capital Partners EG, L.P. | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | |
| 15.05.2026 | Venrock Healthcare Capital Partners III, L.P. | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | |
| 15.05.2026 | Bong Y. Koh | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | |
| 15.05.2026 | VHCP Management III, LLC | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | |
| 15.05.2026 | VHCP Management EG, LLC | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | |
| 15.05.2026 | VHCP Co-Investment Holdings III, LLC | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | |
| 15.05.2026 | Nimish Shah | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | |
| 15.05.2026 | Polar Capital LLP | Passiv (13G/A) | 8,46 % | 5.056.807 | -0,01 pp | |
| 15.05.2026 | Polar Capital Holdings Plc | Passiv (13G/A) | 8,46 % | 5.056.807 | -0,01 pp | |
| 15.05.2026 | Polar Capital Funds PLC - Biotechnology Fund | Passiv (13G/A) | 8,46 % | 5.056.807 | -0,01 pp | |
| 15.05.2026 | Polar Capital LLP | Passiv (13G/A) | 8,47 % | 59.800.406 | +3,30 pp | |
| 15.05.2026 | Polar Capital Holdings Plc | Passiv (13G/A) | 8,47 % | 59.800.406 | +3,30 pp | |
| 15.05.2026 | Polar Capital Funds PLC - Biotechnology Fund | Passiv (13G/A) | 8,47 % | 59.800.406 | +3,30 pp | |
| 15.05.2026 | Kiselak Tomas | Passiv (13G/A) | 3,10 % | 1.855.644 | Neu | |
| 15.05.2026 | Peter Harwin | Passiv (13G/A) | 3,10 % | 1.855.644 | -3,20 pp | |
| 15.05.2026 | Fairmount Healthcare Fund II L.P. | Passiv (13G/A) | 3,10 % | 1.855.644 | -3,20 pp | |
| 15.05.2026 | Fairmount Funds Management LLC | Passiv (13G/A) | 3,10 % | 1.855.644 | -3,20 pp | |
| 15.05.2026 | Ryan Wilder | Passiv (13G/A) | 5,40 % | 3.250.000 | -1,10 pp | |
| 15.05.2026 | Vestal Point Capital, LP | Passiv (13G/A) | 5,40 % | 3.250.000 | -1,10 pp | |
| 17.02.2026 | Vestal Point Capital, LP | Passiv (13G) | 6,50 % | 3.830.000 | Neu | |
| 17.02.2026 | Ryan Wilder | Passiv (13G) | 6,50 % | 3.830.000 | Neu | |
| 14.11.2025 | Venrock Healthcare Capital Partners EG, L.P. | Passiv (13G/A) | 5,40 % | 3.226.331 | -3,10 pp | |
| 14.11.2025 | Venrock Healthcare Capital Partners III, L.P. | Passiv (13G/A) | 5,40 % | 3.226.331 | -1,80 pp | |
| 14.11.2025 | Nimish Shah | Passiv (13G/A) | 5,40 % | 3.226.331 | Neu | |
| 14.11.2025 | VHCP Management EG, LLC | Passiv (13G/A) | 5,40 % | 3.226.331 | -3,10 pp | |
| 14.11.2025 | Bong Y. Koh | Passiv (13G/A) | 5,40 % | 3.226.331 | Neu | |
| 14.11.2025 | VHCP Co-Investment Holdings III, LLC | Passiv (13G/A) | 5,40 % | 3.226.331 | -3,10 pp | |
| 14.11.2025 | VHCP Management III, LLC | Passiv (13G/A) | 5,40 % | 3.226.331 | -3,10 pp | |
| 05.11.2025 | Abigail P. Johnson | Passiv (13G/A) | 13,30 % | 7.870.219 | Neu | |
| 05.11.2025 | FMR LLC | Passiv (13G/A) | 13,30 % | 7.870.219 | Neu | |
| 14.08.2025 | Commodore Capital LP | Passiv (13G/A) | 9,90 % | 6.022.957 | +6,40 pp | |
| 14.08.2025 | Michael Kramarz | Passiv (13G/A) | 9,90 % | 6.022.957 | Neu | |
| 14.08.2025 | Commodore Capital Master LP | Passiv (13G/A) | 9,90 % | 6.022.957 | Neu | |
| 14.08.2025 | Robert Egen Atkinson | Passiv (13G/A) | 9,90 % | 6.022.957 | Neu | |
| 14.08.2025 | Polar Capital Holdings Plc | Passiv (13G) | 5,17 % | 2.536.881 | +0,28 pp | |
| 14.08.2025 | Polar Capital Funds PLC - Biotechnology Fund | Passiv (13G) | 5,17 % | 2.536.881 | +0,28 pp |
Stammdaten
Enliven Therapeutics, Inc., ein Biopharmazeutika-Unternehmen im klinischen Stadium, konzentriert sich auf die Entdeckung und Entwicklung von Kleinmolekül-Inhibitoren für Krebspatienten. Seine Pipeline von Kleinmolekül-Kinase-Inhibitoren umfasst ELVN-001, das in einer Phase-1-Studie bei Erwachsenen mit chronischer myeloischer Leukämie evaluiert wird, und ELVN-002, für das eine Phase-1-Studie zur Evaluierung bei Patienten mit Krebserkrankungen mit abnormaler HER2-Expression aktiviert wurde. Das Unternehmen ist in Boulder, Colorado ansässig.
Unternehmen & Branche
| Name | Enliven Therapeutics, Inc. |
|---|---|
| Ticker | ELVN |
| CIK | 0001672619 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 29337E102 |
|---|---|
| ISIN | US29337E1029 |
| Typ | Common Stock |
| Marktkapitalisierung | 2,40 Mrd. USD |
| Beta | 0,29 |
Bewertung
| KBV (P/B) | 5,22 |
|---|---|
| FCF-Rendite | -2,9 % vs. -19,8 % (2021) ▲ |
Qualität & Bilanz
| ROIC | -22,5 % |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | – | – | 2,32 | 3,55 | 1,99 | |
| FCF-Rendite | -19,8 % | -54,9 % | -10,7 % | -6,6 % | -7,7 % | |
| Qualität & Bilanz | ||||||
| ROIC | – | – | -29,1 % | -28,7 % | -22,5 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | -23.627.000 | -0,38 | 464.852.000 | 453.365.000 | |
| 2025-12-31 | 10-K | -103.694.000 | -1,83 | 476.168.000 | 459.600.000 | |
| 2025-09-30 | 10-Q | -20.148.000 | -0,32 | 490.875.000 | 476.122.000 | |
| 2025-06-30 | 10-Q | -25.335.000 | -0,49 | 503.887.000 | 488.472.000 | |
| 2025-03-31 | 10-Q | -28.544.000 | -0,57 | 302.570.000 | 288.296.000 | |
| 2024-12-31 | 10-K | -89.024.000 | -1,89 | 325.760.000 | 309.845.000 | |
| 2024-09-30 | 10-Q | -23.156.000 | -0,48 | 305.430.000 | 288.403.000 | |
| 2024-06-30 | 10-Q | -19.950.000 | -0,41 | 327.043.000 | 304.932.000 | |
| 2024-03-31 | 10-Q | -22.738.000 | -0,54 | 342.777.000 | 317.712.000 | |
| 2023-12-31 | 10-K | -71.584.000 | -2,01 | 271.867.000 | 245.906.000 | |
| 2023-09-30 | 10-Q | -20.769.000 | -0,51 | 274.041.000 | 261.748.000 | |
| 2023-06-30 | 10-Q | -16.721.000 | -0,41 | 288.501.000 | 278.994.000 | |
| 2023-03-31 | 10-Q | -14.724.000 | -0,80 | 302.866.000 | 291.416.000 | |
| 2022-12-31 | 10-K | -37.662.000 | -12,05 | 83.298.000 | -76.825.000 | |
| 2022-09-30 | 10-Q | -10.554.000 | -3,27 | 59.104.000 | -68.097.000 | |
| 2022-06-30 | 10-Q | -8.889.000 | -2,86 | 64.666.000 | -58.713.000 | |
| 2022-03-31 | 10-Q | -8.669.000 | -3,01 | 81.602.000 | -50.610.000 | |
| 2021-12-31 | 10-K | -51.384.000 | -2,37 | 93.646.000 | -42.887.000 | |
| 2021-09-30 | 10-Q | -13.647.000 | -0,74 | 107.027.000 | 99.373.000 | |
| 2021-06-30 | 10-Q | -13.161.000 | -0,74 | 72.468.000 | 64.967.000 |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | – | -0,38 |
| Q3 2025 | 30.09.2025 | 12.11.2025 | – | -0,32 |
| Q2 2025 | 30.06.2025 | 12.11.2025 | – | -0,49 |
| Q1 2025 | 31.03.2025 | 07.05.2026 | – | -0,57 |
| Q3 2024 | 30.09.2024 | 12.11.2025 | – | -0,48 |
| Q2 2024 | 30.06.2024 | 12.11.2025 | – | -0,41 |
| Q1 2024 | 31.03.2024 | 12.11.2025 | – | -0,54 |
| Q3 2023 | 30.09.2023 | 13.11.2024 | – | -0,51 |
| Q2 2023 | 30.06.2023 | 13.11.2024 | – | -0,41 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | – | – | SEC » |
| 03.03.2026 | 10-K | 31.12.2025 | 62 Tage | SEC » |
| 12.11.2025 | 10-Q | 30.09.2025 | 43 Tage | SEC » |
| 13.08.2025 | 10-Q | 30.06.2025 | 44 Tage | SEC » |
| 14.05.2025 | 10-Q | 31.03.2025 | 44 Tage | SEC » |
| 13.03.2025 | 10-K | 31.12.2024 | 72 Tage | SEC » |
| 13.11.2024 | 10-Q | 30.09.2024 | 44 Tage | SEC » |
| 13.08.2024 | 10-Q | 30.06.2024 | 44 Tage | SEC » |
| 14.05.2024 | 10-Q | 31.03.2024 | 44 Tage | SEC » |
| 14.03.2024 | 10-K | 31.12.2023 | 74 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 10.08.2023 | 10-Q | 30.06.2023 | 41 Tage | SEC » |
| 11.05.2023 | 10-Q | 31.03.2023 | 41 Tage | SEC » |
| 10.02.2023 | 10-K | 31.12.2022 | 41 Tage | SEC » |
| 25.10.2022 | 10-Q | 30.09.2022 | 25 Tage | SEC » |
| 03.08.2022 | 10-Q | 30.06.2022 | 34 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 15.03.2022 | 10-K | 31.12.2021 | 74 Tage | SEC » |
| 09.11.2021 | 10-Q | 30.09.2021 | 40 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 11.05.2021 | 10-Q | 31.03.2021 | 41 Tage | SEC » |
| 05.03.2021 | 10-K | 31.12.2020 | 64 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 14.08.2020 | 10-Q | 30.06.2020 | 45 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 1.01 of Form 8-K, the information contained in Item 5.02 is incorporated by reference herein. Item 2.01. Completion of… |
| 14.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 25.10.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-14 | 10.394 | 43,56 | 452.763 |
| 2026-04-20 | 367 | 48,11 | 17.656 |
| 2026-04-13 | 55 | 45,32 | 2.493 |
| 2026-04-06 | 15.603 | 38,83 | 605.864 |
| 2026-04-02 | 15.707 | 37,79 | 593.568 |
| 2026-03-31 | 1.079 | 36,59 | 39.481 |
| 2026-03-30 | 18 | 38,83 | 699 |
| 2026-03-19 | 43 | 27,25 | 1.172 |
| 2026-03-10 | 3.406 | 29,73 | 101.260 |
| 2026-03-09 | 8.929 | 29,44 | 262.870 |
| 2026-03-06 | 2.455 | 29,29 | 71.907 |
| 2026-03-05 | 23.773 | 29,98 | 712.715 |
| 2026-03-04 | 30.016 | 28,75 | 862.960 |
| 2026-03-03 | 23.981 | 29,50 | 707.440 |
| 2026-02-27 | 659 | 29,62 | 19.520 |
| 2026-02-26 | 25 | 29,28 | 732 |
| 2026-02-23 | 890 | 26,02 | 23.158 |
| 2026-02-20 | 28.794 | 26,16 | 753.251 |
| 2026-02-18 | 59.914 | 26,13 | 1.565.553 |
| 2026-02-17 | 9.292 | 26,72 | 248.282 |
| 2026-02-13 | 2.384 | 27,16 | 64.749 |
| 2026-02-12 | 4 | 28,01 | 112 |
| 2026-02-11 | 2.252 | 27,93 | 62.898 |
| 2026-02-09 | 298 | 29,42 | 8.767 |
| 2026-02-06 | 5.098 | 26,99 | 137.595 |
| 2026-02-03 | 292 | 28,17 | 8.226 |
| 2026-02-02 | 292 | 26,45 | 7.723 |
| 2026-01-29 | 7.132 | 25,38 | 181.010 |
| 2026-01-23 | 47 | 27,03 | 1.270 |
| 2026-01-22 | 63 | 27,21 | 1.714 |
| 2026-01-21 | 147 | 27,05 | 3.976 |
| 2026-01-20 | 6.831 | 26,71 | 182.456 |
| 2026-01-16 | 25.143 | 25,17 | 632.849 |
| 2026-01-15 | 225 | 26,05 | 5.861 |
| 2026-01-14 | 512 | 25,75 | 13.184 |
| 2026-01-12 | 4.402 | 26,00 | 114.452 |
| 2026-01-09 | 298.601 | 23,25 | 6.942.473 |
| 2026-01-07 | 1.894 | 15,14 | 28.675 |
| 2026-01-05 | 55 | 15,54 | 855 |
| 2025-12-31 | 4.172 | 15,55 | 64.875 |
| 2025-12-30 | 1.421 | 15,94 | 22.651 |
| 2025-12-23 | 2 | 17,93 | 36 |
| 2025-12-22 | 242 | 16,87 | 4.083 |
| 2025-12-19 | 73 | 16,68 | 1.218 |
| 2025-12-18 | 2.632 | 16,02 | 42.165 |
| 2025-12-17 | 3.098 | 16,91 | 52.387 |